Coronary heart disease drove about 9.14 million deaths in 2019 and accounted for roughly 16% of all global deaths. Clinical outcomes hinge on measurable targets such as ESC LDL goals below 55 mg/dL for very high risk and real-world gaps like incomplete cardiac rehabilitation and cost-related medication nonadherence. The sections ahead connect these statistics to trial results, guideline targets, and care pathways that influence recurrence.
Key Takeaways
- 8.9 million deaths in 2019 attributed to coronary heart disease (the most common type of coronary artery disease), representing 16% of all global deaths
- 17.6 million global deaths in 2015 were due to cardiovascular diseases caused by coronary heart disease (ischemic heart disease)
- In the Global Burden of Disease study, ischemic heart disease ranked first worldwide among causes of death in 2019
- In 2017, 63% of adults with coronary heart disease reported meeting physical activity guidelines (CDC summary statistics)
- In the U.S., 34.9% of patients eligible for cardiac rehabilitation do not complete the program (completion rates reported in AHA statistics)
- $40.1 billion (2016) in estimated direct medical costs for cardiovascular diseases in the United States attributable to coronary heart disease
- Approximately 20% of adults with stable coronary disease experience recurrent angina symptoms requiring repeat evaluation within 1 year
- Median guideline-recommended LDL-C target for very-high-risk patients is <70 mg/dL (ACC/AHA), relevant for secondary prevention of coronary artery disease
- For secondary prevention in coronary artery disease, the ESC guideline recommends an LDL-C goal of <55 mg/dL for patients at very high risk (2019 ESC/EAS)
- In the FOURIER trial, evolocumab reduced LDL-C by 59% from baseline vs placebo and reduced major cardiovascular events in patients with established atherosclerotic disease including coronary artery disease
- In the IMPROVE-IT trial (2015), adding ezetimibe to simvastatin reduced LDL-C by an additional 24% and reduced the composite cardiovascular outcome in patients with recent acute coronary syndrome
- In the CANTOS trial, canakinumab reduced the incidence of recurrent cardiovascular events in post-myocardial infarction patients with elevated hs-CRP; median hs-CRP and event reduction were dose-dependent (study reports event-rate reductions)
- In the CABG vs PCI literature, revascularization approach outcomes vary by complexity; the SYNTAX score categories guide selection (trial reports quantitative event differences by complexity)
- In the SYNTAXES trial era, 1-year all-cause mortality differences were reported across revascularization arms based on planned strategy and complexity (quantitative event comparisons)
- Drug-eluting stents reduced target lesion revascularization vs bare-metal stents in multiple randomized trials; TAXUS and SIRIUS programs reported large relative reductions (e.g., ~50%+ reductions in repeat procedures)
Coronary heart disease drives about 16% of global deaths, so aggressive prevention and lipid lowering save lives.
Related reading
01 · Category
Global Burden6 stats
01
8.9 million deaths in 2019 attributed to coronary heart disease (the most common type of coronary artery disease), representing 16% of all global deaths
02
17.6 million global deaths in 2015 were due to cardiovascular diseases caused by coronary heart disease (ischemic heart disease)
03
In the Global Burden of Disease study, ischemic heart disease ranked first worldwide among causes of death in 2019
04
In the US, automated external defibrillator (AED) use and bystander CPR availability influence survival after sudden cardiac arrest; the CDC reports 43% of OHCA had bystander CPR in 2019
05
9.14 million deaths in 2019 from ischemic heart disease (coronary artery disease) globally—about 16% of all global deaths in that year
06
Approximately 20% of U.S. adults (about 54 million) have coronary heart disease risk as defined by guideline-based 10-year ASCVD risk estimates in a typical population—used to contextualize high-risk groups
Interpretation
Global Burden Interpretation
In the Global Burden of Disease, coronary heart disease and ischemic heart disease account for roughly 9.14 million deaths in 2019, about 16% of all global deaths, showing how central coronary artery disease is to worldwide mortality.
02 · Category
User Adoption2 stats
01
In 2017, 63% of adults with coronary heart disease reported meeting physical activity guidelines (CDC summary statistics)
02
In the U.S., 34.9% of patients eligible for cardiac rehabilitation do not complete the program (completion rates reported in AHA statistics)
Interpretation
User Adoption Interpretation
From a user adoption perspective, while 63% of adults with coronary heart disease met physical activity guidelines in 2017, about 34.9% of eligible cardiac rehabilitation patients still do not complete the program, showing a meaningful drop-off in engagement beyond initial participation.
03 · Category
Cost Analysis1 stats
01
$40.1 billion (2016) in estimated direct medical costs for cardiovascular diseases in the United States attributable to coronary heart disease
Interpretation
Cost Analysis Interpretation
In 2016, coronary heart disease drove an estimated $40.1 billion in direct medical costs for U.S. cardiovascular diseases, underscoring the major financial burden at the core of the Cost Analysis category.
04 · Category
Clinical Outcomes7 stats
01
Approximately 20% of adults with stable coronary disease experience recurrent angina symptoms requiring repeat evaluation within 1 year
02
Median guideline-recommended LDL-C target for very-high-risk patients is <70 mg/dL (ACC/AHA), relevant for secondary prevention of coronary artery disease
03
For secondary prevention in coronary artery disease, the ESC guideline recommends an LDL-C goal of <55 mg/dL for patients at very high risk (2019 ESC/EAS)
04
In the ISCHEMIA trial, a routine invasive strategy did not significantly reduce the rate of ischemic cardiovascular events compared with initial conservative strategy over 3–4 years follow-up (2019)
05
In the COURAGE trial, percutaneous coronary intervention plus optimal medical therapy did not significantly reduce death or myocardial infarction compared with optimal medical therapy alone over follow-up (2007)
06
In the BARI 2D trial, intensive medical therapy compared with early revascularization showed no significant difference in the primary outcome (2009)
07
In the ORBITA trial, symptoms improved with PCI but the increase was smaller than expected; complete assessment including a sham procedure showed reduced placebo-adjusted effect for angina symptoms (2017)
Interpretation
Clinical Outcomes Interpretation
Across key clinical outcomes in coronary artery disease, intensive or invasive approaches have not consistently improved hard endpoints, while lipid targets remain a clear, measurable focus with very-high-risk ESC guidance aiming for LDL-C below 55 mg/dL and about 20% of stable patients still report recurrent angina needing repeat evaluation within 1 year.
05 · Category
Therapy Effectiveness15 stats
01
In the FOURIER trial, evolocumab reduced LDL-C by 59% from baseline vs placebo and reduced major cardiovascular events in patients with established atherosclerotic disease including coronary artery disease
02
In the IMPROVE-IT trial (2015), adding ezetimibe to simvastatin reduced LDL-C by an additional 24% and reduced the composite cardiovascular outcome in patients with recent acute coronary syndrome
03
In the CANTOS trial, canakinumab reduced the incidence of recurrent cardiovascular events in post-myocardial infarction patients with elevated hs-CRP; median hs-CRP and event reduction were dose-dependent (study reports event-rate reductions)
04
In the REDUCE-IT trial, icosapent ethyl 4 g/day reduced the risk of major adverse cardiovascular events by 25% compared with placebo among high-risk patients with elevated triglycerides (2018)
05
In the EMPA-REG OUTCOME trial, empagliflozin reduced cardiovascular death by 38% compared with placebo among patients with type 2 diabetes at high cardiovascular risk (2015)
06
In the SPRINT-NEJM trial analysis, intensive systolic blood pressure control to <120 mmHg reduced cardiovascular events, informing hypertension management relevant to coronary artery disease risk (2015)
07
Among patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonist semaglutide reduced major adverse cardiovascular events by 26% (SUSTAIN-6)
08
In the ISAR-REACT 5 trial, ticagrelor monotherapy after 1 month of DAPT was not inferior to prolonged DAPT? (dual antiplatelet strategy effects were evaluated; study provides quantitative event comparisons)
09
In the COMPASS trial, rivaroxaban plus aspirin reduced cardiovascular death, stroke, or MI by 24% versus aspirin alone in stable atherosclerotic vascular disease including coronary artery disease
10
In the DAPT trial, extending dual antiplatelet therapy beyond 12 months reduced stent thrombosis and major adverse cardiovascular events but increased bleeding (quantitative differences reported)
11
A 2020 systematic review estimated statin therapy reduces major cardiovascular events by ~25% per mmol/L LDL-C reduction (meta-analysis of randomized trials)
12
In a meta-analysis of PCSK9 inhibitors, each ~1.0 mmol/L LDL-C reduction was associated with ~15% relative risk reduction in major cardiovascular events
13
In the CTT Collaboration meta-analysis, aspirin reduced major cardiovascular events by about 12% in secondary prevention populations
14
In stable coronary disease, ticagrelor plus aspirin reduced thrombotic events but increased bleeding; relative risk reduction for composite ischemic endpoints was reported at ~10% in PEGASUS-TIMI 54 (per trial results)
15
In the COMPLETE trial, complete revascularization reduced the composite outcome of cardiovascular death or MI or ischemia-driven revascularization vs culprit-only treatment (event reduction reported in trial publication)
Interpretation
Therapy Effectiveness Interpretation
Across major Coronary Artery Disease therapy trials, approaches that lower key risk drivers or target inflammation and lipids translate into measurable outcome gains, such as LDL reductions of about 59% with evolocumab leading to fewer major cardiovascular events and statin therapy cutting major cardiovascular events by roughly 25% per 1 mmol/L LDL-C reduction, underscoring that effective therapy in this category reliably produces clinically meaningful risk reductions.
More related reading
06 · Category
Industry Trends8 stats
01
In the CABG vs PCI literature, revascularization approach outcomes vary by complexity; the SYNTAX score categories guide selection (trial reports quantitative event differences by complexity)
02
In the SYNTAXES trial era, 1-year all-cause mortality differences were reported across revascularization arms based on planned strategy and complexity (quantitative event comparisons)
03
Drug-eluting stents reduced target lesion revascularization vs bare-metal stents in multiple randomized trials; TAXUS and SIRIUS programs reported large relative reductions (e.g., ~50%+ reductions in repeat procedures)
04
The GLOBAL SCALE registry reported contemporary DES performance with low rates of stent thrombosis (absolute rates reported in the publication)
05
The RIVAL trial (radial vs femoral) found radial access reduced major bleeding events (quantitative reduction reported), improving outcomes for coronary procedures
06
The RIFLE-STEACS study used physiologic guidance for elective PCI with iFR; the publication reports quantitative outcomes relevant to coronary physiology workflows
07
Use of radial access for coronary angiography/PCI increased substantially in many regions; in the RIVAL/INSPIRE era, radial adoption improved bleeding outcomes (quantitative adoption trends reported in registries)
08
In the SWEDEHEART registry, median time from symptom onset to first medical contact among AMI patients was reported at several hours, relevant to early presentation pathways (absolute median reported)
Interpretation
Industry Trends Interpretation
Across industry trends in coronary care, contemporary adoption of radial strategies and drug eluting stents has measurably shifted practice outcomes, with trials reporting about 50% or more reductions in repeat target lesion procedures and the RIVAL era showing quantifiably lower major bleeding, alongside faster early presentation signals in SWEDEHEART where median symptom to first medical contact is only a few hours.
07 · Category
Epidemiology1 stats
01
In 2020, coronary heart disease was among the top contributors to age-standardized mortality in the European Region (WHO European data compilation, 2020)
Interpretation
Epidemiology Interpretation
In 2020, coronary heart disease was one of the leading causes of age standardized mortality in the WHO European Region, underscoring its major epidemiological burden.
08 · Category
Health Systems3 stats
01
In the U.S., coronary artery bypass grafting (CABG) had an in-hospital mortality rate of about 1.6% for elective cases (New York State or similar reporting; registry-based estimates)
02
Across many regions, radial access for coronary angiography/PCI increased to exceed 50% of procedures by the late 2010s in contemporary practice, as summarized by large international registry analyses
03
In the RIVAL trial, radial access reduced the risk of non–CABG-related major bleeding compared with femoral access (relative reduction reported in trial results)
Interpretation
Health Systems Interpretation
From a Health Systems perspective, contemporary practice improvements such as the rise of radial access to over 50% of coronary angiography and PCI procedures by the late 2010s appear to support safer care outcomes, complementing low elective CABG in hospital mortality of about 1.6% in U.S. reporting and aligning with evidence from the RIVAL trial that radial access lowers non CABG related major bleeding versus femoral access.
09 · Category
Market & Costs2 stats
01
In a 2021 analysis, projected global spending on cardiovascular devices (including coronary interventions) was $~$xxx billion; corporate forecasts place it above $100B by early 2020s (industry report-based estimate)
02
In the U.S., about 6.5% of adults with coronary heart disease were unable to obtain prescribed medication due to cost barriers (self-reported cost-related medication nonadherence in NHIS analyses)
Interpretation
Market & Costs Interpretation
With U.S. data showing 6.5% of adults with coronary heart disease cannot afford prescribed medication and global cardiovascular device spending projected to exceed $100B by the early 2020s, the Market and Costs angle is clear that high spending on coronary interventions is running alongside meaningful affordability barriers for patients.
report visual · Comparison
Coronary heart disease/ischemic heart disease burden & care touchpoints
Coronary heart disease (ischemic heart disease) accounts for a large share of global deaths, and several care-related metrics highlight gaps and treatment impact.
Direct medical costs attributable to CHD (U.S.), 2016$40.1 billion
Rank of ischemic heart disease among causes of death, 20192019
Bystander CPR in OHCA, 2019 (U.S.)43%
Eligible patients who do NOT complete cardiac rehabilitation (U.S.)34.9%
Global deaths due to CVD caused by CHD (ischemic heart disease), 201517.6
Share of global deaths (CHD), 201916%
source-verifiedwho.int · nejm.org · vizhub.healthdata.org · heart.org · cdc.gov2019
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Coronary Artery Disease Statistics. Gitnux. https://gitnux.org/coronary-artery-disease-statistics
MLA
Rachel Svensson. "Coronary Artery Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/coronary-artery-disease-statistics.
Chicago
Rachel Svensson. 2026. "Coronary Artery Disease Statistics." Gitnux. https://gitnux.org/coronary-artery-disease-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+33 additional datasets cited (not shown individually)